183 related articles for article (PubMed ID: 25753440)
21. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline.
Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM
Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325
[TBL] [Abstract][Full Text] [Related]
22. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
23. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
24. Predictive markers in breast cancer: An update on ER and HER2 testing and reporting.
Calhoun BC; Collins LC
Semin Diagn Pathol; 2015 Sep; 32(5):362-9. PubMed ID: 25770732
[TBL] [Abstract][Full Text] [Related]
25. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
26. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
27. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.
Rakha EA; Starczynski J; Lee AH; Ellis IO
Histopathology; 2014 Apr; 64(5):609-15. PubMed ID: 24382093
[TBL] [Abstract][Full Text] [Related]
28. [Comments on American Society of Clinical Oncology/College of American Pathologists for HER2 testing in breast cancer].
Gong Y; Xiao CH; Fu L
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):795-8. PubMed ID: 20193452
[No Abstract] [Full Text] [Related]
29. RAI1 Alternate Probe Identifies Additional Breast Cancer Cases as Amplified Following Equivocal HER2 Fluorescence In Situ Hybridization Testing: Experience From a National Reference Laboratory.
Hui L; Geiersbach KB; Downs-Kelly E; Gulbahce HE
Arch Pathol Lab Med; 2017 Feb; 141(2):274-278. PubMed ID: 27959582
[TBL] [Abstract][Full Text] [Related]
30. Human epidermal growth factor receptor 2 testing in invasive breast cancer: should histological grade, type and oestrogen receptor status influence the decision to repeat testing?
Rakha EA; Pigera M; Shin SJ; D'Alfonso T; Ellis IO; Lee AH
Histopathology; 2016 Jul; 69(1):20-4. PubMed ID: 26542743
[TBL] [Abstract][Full Text] [Related]
31. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
32. [Assessment and significance of human epidermal growth factor receptor 2 gene status in breast cancer with polysomy of chromosome 17].
Zhang H; Si JW; Zhang S; Wang Y; Li D; Li T
Zhonghua Zhong Liu Za Zhi; 2016 Feb; 38(2):124-9. PubMed ID: 26899332
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study.
Sneige N; Hess KR; Multani AS; Gong Y; Ibrahim NK
Cancer; 2017 Apr; 123(7):1115-1123. PubMed ID: 27893937
[TBL] [Abstract][Full Text] [Related]
34. ASCO-CAP guidelines for breast predictive factor testing: an update.
Hammond ME
Appl Immunohistochem Mol Morphol; 2011 Dec; 19(6):499-500. PubMed ID: 22089488
[TBL] [Abstract][Full Text] [Related]
35. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
Ballinger TJ; Sanders ME; Abramson VG
Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
[TBL] [Abstract][Full Text] [Related]
36. Precision medicine in breast cancer.
Naito Y; Urasaki T
Chin Clin Oncol; 2018 Jun; 7(3):29. PubMed ID: 30056731
[TBL] [Abstract][Full Text] [Related]
37. Human epidermal growth factor receptor 2 testing: where are we?
De P; Smith BR; Leyland-Jones B
J Clin Oncol; 2010 Oct; 28(28):4289-92. PubMed ID: 20697080
[No Abstract] [Full Text] [Related]
38. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
Satti MB
Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
[TBL] [Abstract][Full Text] [Related]
39. New guidelines for HER2+ breast cancer.
Cancer Discov; 2014 Jul; 4(7):OF2. PubMed ID: 25002626
[TBL] [Abstract][Full Text] [Related]
40. Precise ERBB2 copy number assessment in breast cancer by means of molecular inversion probe array analysis.
Christgen M; van Luttikhuizen JL; Raap M; Braubach P; Schmidt L; Jonigk D; Feuerhake F; Lehmann U; Schlegelberger B; Kreipe HH; Steinemann D
Oncotarget; 2016 Dec; 7(50):82733-82740. PubMed ID: 27716627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]